2021

• Vianello E., Gonzalez-Dias P, van Veen S, Engele CG, Quinten E, Monath TP, Medaglini D, VSV-EBOVAC and VSV-EBOPLUS Consortia, Santoro F, Huttner A, Dubey S, Eichberg M, Ndungu FM, Kremsner PG, Essone PN, Agnandji ST, Siegrist CA, Nakaya HI, Ottenhoff THM, and Haks MC.  Transcriptomic signatures induced by rVSVΔG‐ZEBOV-GP vaccination in adult cohorts in Europe, Africa and North America. The Lancet Microbe. https://doi.org/10.1016/S2666-5247(21)00235-4
• Francesco Santoro, Alessia Donato, Simone Lucchesi, Sara Sorgi, Alice Gerlini, Marielle C. Haks, Tom H. M. Ottenhoff, Patricia Gonzalez-Dias, VSV-EBOVAC Consortium, VSV-EBOPLUS Consortium, Helder I. Nakaya, Angela Huttner, Claire-Anne Siegrist, Donata Medaglini and Gianni Pozzi. Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine. Vaccines (Basel) 2021 Jan 20;9(2):E67. doi: 10.3390/vaccines9020067

2020

• David Pejoski, Casimir de Rham, Paola Martinez-Murillo, Francesco Santoro, Floriane Auderset, Donata Medaglini, Gianni Pozzi, Maria Vono, Paul-Henri Lambert, Angela Huttner, Mariëlle C. Haks, Tom H. M. Ottenhoff, Jean Villard, Claire-Anne Siegrist, the VEBCON Consortium, VSV-EBOVAC Consortium & VSV-EBOPLUS Consortium. Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination. npj Vaccines. 5/1, doi: 10.1038/s41541-020-0179-4
• Bache Emmanuel Bache, Martin P Grobusch & Selidji Todagbe Agnandji. Safety, immunogenicity and risk–benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I–III clinical trials across regions. Future Microbiol. 2020 Jan;15:85-106. doi: 10.2217/fmb-2019-023

2019

• Patrícia Gonzalez-Dias, Eva K. Lee, Sara Sorgi, Diógenes S. de Lima, Alysson H. Urbanski, Eduardo Lv Silveira & Helder I. Nakaya. Methods for predicting vaccine immunogenicity and reactogenicity. Hum Vaccin Immunother. 2020;16(2):269-276. doi: 10.1080/21645515.2019.1697110

2018

• Medaglini D, Santoro F, Siegrist CA. Correlates of vaccine-induced protective immunity against Ebola virus disease. Semin Immunol. 2018 Jul 21. doi: 10.1016/j.smim.2018.07.003

• Huttner A, Agnandji ST, Combescure C, Fernandes JF, Bache EB, Kabwende L, Ndungu FM, Brosnahan J, Monath TP, Lemaître B, Grillet S, Botto M, Engler O, Portmann J, Siegrist D, Bejon P, Silvera P, Kremsner P, Siegrist CA; VEBCON; VSV-EBOVAC; VSV-EBOPLUS Consortia. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2018 Jul;18(7):738-748. doi: 10.1016/S1473-3099(18)30165-8
• Huttner A. and Siegrist CA; Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?. Expert Rev Vaccines. 2018 (12):1105-1110. doi: 10.1080/14760584.2018.1546582